Protego Announces FDA IND Clearance for Phase 2/3 Study of PROT-001 in AL Amyloidosis
– Clearance enables initiation of SHIELD-AL, a pivotal study in newly diagnosed patients with lambda AL amyloidosis – Investigational oral light chain stabilizer to be evaluated as an add-on to standard-of-care plasma cell-directed therapy SAN […]
